Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives

Eur Respir Rev. 2018 Feb 7;27(147):170113. doi: 10.1183/16000617.0113-2017. Print 2018 Mar 31.

Abstract

Chronic obstructive pulmonary disease (COPD) is a disabling condition that is characterised by poorly reversible airflow limitation and inflammation. Acute exacerbations of COPD are a common cause of hospitalisation and death among COPD patients. Several biochemical markers have been studied as outcome predictors in COPD; however, their measurement often requires significant time and resources. Relatively simple biomarkers of inflammation calculated from routine complete blood count tests, such as the neutrophil to lymphocyte ratio (NLR), might also predict COPD progression and outcomes. This review discusses the available evidence from studies investigating the associations between the NLR, COPD exacerbations and death in this patient group.

Publication types

  • Review

MeSH terms

  • Comorbidity
  • Diffusion of Innovation
  • Disease Progression
  • Evidence-Based Medicine / trends*
  • Forecasting
  • Health Status
  • Humans
  • Lymphocyte Count
  • Lymphocytes*
  • Neutrophils*
  • Predictive Value of Tests
  • Pulmonary Disease, Chronic Obstructive / blood*
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / epidemiology
  • Pulmonary Disease, Chronic Obstructive / therapy
  • Pulmonary Medicine / trends*
  • Respiratory Tract Infections / blood
  • Respiratory Tract Infections / epidemiology
  • Risk Factors
  • Treatment Outcome